Revenue: ₹2,026 crore, increased 29% year-over-year (YoY) from ₹1,570 crore in Q1 FY26, and increased 12% quarter-over-quarter (QoQ) from ₹1,812 crore in Q4 FY26.
Gross Margins: 62.7%, increased by 3.3 percentage points YoY from 59.4%, and increased by 1.3 percentage points QoQ from 61.4%.
EBITDA: ₹644 crore, increased 66% YoY from ₹389 crore, and increased 23% QoQ from ₹523 crore. EBITDA margin: 31.8%, increased by 7.0 percentage points YoY and 2.9 percentage points QoQ.
Net Profit: ₹368 crore, increased 126% YoY from ₹163 crore, and increased 32% QoQ from ₹279 crore. Net profit margin: 18.2%, increased by 7.8 percentage points YoY and 2.8 percentage points QoQ.
EPS: ₹6.8, increased 127% YoY from ₹3.0, and increased 31% QoQ from ₹5.2.
R&D Spends: ₹118 crore (5.8% of revenue), including Capex R&D spends of ₹35 crore towards Advanced Biologics (Gene therapy and ADC). R&D increased by 74% YoY.
Business Highlights
Strong growth driven by CDMO business, with commercial projects supplies and steady momentum in Affordable Medicines segment.
CDMO revenue share increased, contributing to margin expansion and operational leverage.
Affordable Medicines segment maintained healthy market dynamics and order book, with consistent deliveries.
CAPEX and Investment Plans
Cumulative CAPEX of over ₹3,000 crore planned for FY27 and FY28, with more than 85% allocated to growth projects.
Q1 CAPEX reached 19% of revenue.
Key projects include:
Multiple API blocks, flexible manufacturing, large-scale API capacity, with phase 1 starting in 2027.
Commercial Gene and ADC platform with fill-finish, offering one-stop service for complete ADC programs, qualification by mid-2027.
Enzyme Fermentation plant, commissioning expected by end of 2026, boosting biocatalysis capacity.
Healthy order book, internal pipeline, and key customers supported by demand.
Asset Turnover Ratio (ATR) improving in medium-term inline with 6-year long-term average.
Business Divisions Update
CDMO - Small Molecule
Pipeline: Over 125 projects, diversified across technologies, indications, and customer types.
Priorities: Demand-led capacity creation, investment in technologies, commercial execution of pipeline opportunities, end-to-end execution excellence.
Recent Highlights: Strong visibility on late-stage projects and commercial API supplies, large-scale Peptides manufacturing facility on track, expanding pipeline based on trust and capabilities, deepening client engagement on complex modalities and integrated projects.
BIO - Fermentation Technology
Priorities: Accelerate enzymatic and bio-catalysis application, increase product development throughput, commercial scale capacity creation.
Recent Highlights: Diversified growth and pipeline progress with larger global accounts, improving product and customer mix within CDMO and AOF, traction in enzymatic technology application across small molecule projects, large-scale Fermentation manufacturing site in Vizag on track for December 2026 commissioning.
Affordable Medicines
Priorities: Capacity creation and allocation, cost efficiency, long-term CMO tie-ups, new launches, integrated supplies.
Recent Highlights: Healthy market dynamics across portfolio supporting order book, maintained ARV global leadership, consistent deliveries, ongoing capacity creation and allocation, new launch ramp-up and integrated CMO, expanding footprint across developed and emerging markets. KRKA JV FDF site phase-I to be opened in mid-2027, focusing on High Potent and General OSD capability. Portfolio of 92 DMFs and 96 dossiers filed across US, EU, and Canada.
Advanced Biologics
Gene Therapy and ADC: In-licensed two ADC assets from Aarvik Therapeutics for development and commercialization in India markets. PD team more than doubled in last 6 months. Manufacturing facility build on track with focus on integrated offering (PD, bioconjugation, and finished ADCs capabilities), supporting gram to multi-kg scale for clinical and commercial supplies.
Cell Therapy: Volumes over 660 infusions as of June 2026. Second GMP production facility in Navi Mumbai operationalized in March 2026, with capacity to produce over 2,500 treatments. BCMA Phase-1 trials ongoing for r/r Multiple Myeloma. Cipla partnership for South Africa market progressing well. Licensing opportunities mentioned.
ESG Initiatives
S&P Global ESG Score: 81/100, with key recognitions for ESG programs.
Targets: Over 50% electricity from renewable sources (wind and solar) by 2031 via PPA for all sites. Near-term GHG reduction target validated by SBTi. Sustainable Procurement code established inline with ISO 20400:2017 principles.
Additional Company Information
Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health, with leadership in APIs and FDF across anti-retroviral, oncology, cardiovascular, and gastro therapeutics.
Offers end-to-end CDMO services from early-stage development to commercial production.
Employees: over 8,126, including 3,134+ scientists.
Facilities: 15 approved by global regulators like USFDA, WHO, EMA.
FY2026 revenue: ₹6,813 crore.
Listed on BSE and NSE.
Certified Great Place to Work, MSCI ESG rating "BBB".
Diversified offerings including human and animal health APIs, intermediates, crop science, specialty ingredients for nutrition and cosmetics.
The presentation contains forward-looking statements subject to risks and uncertainties, including market conditions, governmental trends, currency exchange rates, competitive pressures, and regulatory changes. The company undertakes no obligation to update the information.
The presentation is confidential and not a prospectus or offer document under applicable laws.
